Glaukos (GKOS) Projected to Post Earnings on Wednesday

Glaukos (NYSE:GKOS - Get Free Report) is expected to announce its Q1 2025 earnings results after the market closes on Wednesday, April 30th. Analysts expect Glaukos to post earnings of ($0.33) per share and revenue of $102.78 million for the quarter. Glaukos has set its FY 2025 guidance at EPS.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The firm had revenue of $105.50 million during the quarter, compared to analysts' expectations of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. On average, analysts expect Glaukos to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Glaukos Price Performance

Shares of GKOS stock traded down $3.02 during mid-day trading on Monday, reaching $93.66. The stock had a trading volume of 218,999 shares, compared to its average volume of 644,418. The company has a market cap of $5.35 billion, a P/E ratio of -32.60 and a beta of 0.88. Glaukos has a 12-month low of $77.91 and a 12-month high of $163.71. The business has a 50-day simple moving average of $102.37 and a 200 day simple moving average of $130.14. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19.

Insiders Place Their Bets

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the firm's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the transaction, the chief financial officer now owns 53,431 shares of the company's stock, valued at approximately $5,708,568.04. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now owns 72,437 shares of the company's stock, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts recently issued reports on GKOS shares. Mizuho cut their price objective on Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research report on Wednesday, April 16th. Stifel Nicolaus lifted their price objective on Glaukos from $153.00 to $175.00 and gave the stock a "buy" rating in a research report on Tuesday, December 31st. Needham & Company LLC lifted their price target on shares of Glaukos from $149.00 to $176.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Wells Fargo & Company upped their price objective on shares of Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Finally, Truist Financial cut their price target on Glaukos from $185.00 to $140.00 and set a "buy" rating for the company in a report on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Glaukos has an average rating of "Moderate Buy" and a consensus price target of $156.17.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.